aTyr Pharma, Inc. (ATYR)
0.255
-0.02
(-8.37%)
USD |
NASDAQ |
Oct 08, 15:24
aTyr Pharma Enterprise Value : -19.02M for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | -19.02M |
| October 06, 2026 | -18.52M |
| October 05, 2026 | -17.87M |
| October 02, 2026 | -18.14M |
| October 01, 2026 | -17.47M |
| September 30, 2026 | -16.59M |
| September 29, 2026 | -16.13M |
| September 28, 2026 | -17.11M |
| September 25, 2026 | -16.40M |
| September 24, 2026 | -13.20M |
| September 23, 2026 | -9.511M |
| September 22, 2026 | -11.35M |
| September 21, 2026 | -9.746M |
| September 18, 2026 | -10.71M |
| September 17, 2026 | -9.383M |
| September 16, 2026 | -8.638M |
| September 15, 2026 | -8.137M |
| September 14, 2026 | -8.196M |
| September 11, 2026 | -4.155M |
| September 10, 2026 | -3.949M |
| September 09, 2026 | -1.644M |
| September 08, 2026 | 0.8474M |
| September 04, 2026 | 2.466M |
| September 03, 2026 | 3.074M |
| September 02, 2026 | 2.044M |
| Date | Value |
|---|---|
| September 01, 2026 | 0.4256M |
| August 31, 2026 | 5.840M |
| August 28, 2026 | 6.654M |
| August 27, 2026 | 8.086M |
| August 26, 2026 | 7.733M |
| August 25, 2026 | 9.597M |
| August 24, 2026 | 5.673M |
| August 21, 2026 | 2.878M |
| August 20, 2026 | 3.025M |
| August 19, 2026 | 5.948M |
| August 18, 2026 | 3.133M |
| August 17, 2026 | 4.585M |
| August 14, 2026 | 8.518M |
| August 13, 2026 | 7.929M |
| August 12, 2026 | 6.684M |
| August 11, 2026 | 6.066M |
| August 10, 2026 | 5.565M |
| August 07, 2026 | 3.849M |
| August 06, 2026 | 2.927M |
| August 05, 2026 | 5.575M |
| August 04, 2026 | 5.595M |
| August 03, 2026 | 1.946M |
| July 31, 2026 | 1.328M |
| July 30, 2026 | 0.769M |
| July 29, 2026 | 1.063M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.69B |
| ACADIA Pharmaceuticals, Inc. | 2.500B |
| Savara, Inc. | 859.72M |
| Vericel Corp. | 2.017B |
| Biogen, Inc. | 39.88B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.31M |
| Total Expenses (Quarterly) | 10.31M |
| EPS Diluted (Quarterly) | -0.1051 |
| Earnings Yield | -244.2% |
| Normalized Earnings Yield | -244.16 |